This investment will be utilised to fund the growth and expansion of Strand towards becoming a leading integrated diagnostics company.
Strand Life Sciences, a genomic profiling and bioinformatics company, has today raised closed to $13 million of funding by Quadria Capital, a healthcare-focussed private equity investor. India-based HealthQuad Fund and Singapore-based Heritas Venture Fund also contributed to this fund.
This investment will be utilised in the growth and expansion of Strand towards becoming a leading integrated diagnostics company.
Founded in 2000 as a spin-off from the Indian Institute of Science, Strand is in the bioinformatics space, with proprietary data analytical engines for research and clinical applications.
Its customers include leading instrument companies such as Agilent, pharmaceutical companies, diagnostics laboratories, and research laboratories. It has over 220 engineers, scientists and pathologists, and performs diagnostic tests for more than 1,000 hospitals in the country such as HCG, TMC Kolkata, Max Hospitals Delhi, Narayana Hrudayalaya, Apollo Hospitals, etc.
Ramesh Hariharan, CEO, Strand Life Sciences, said “Given their deep operating knowledge and experience of building healthcare businesses in Asia, the partnership with Quadria and HCG will help launch Strand into its next phase of growth and into an era where data analytics and molecular measurements together change diagnosis and treatment paradigms.”
Strand now offers end-to-end capabilities in precision medicine – a complete range of clinical diagnostic offerings including oncology, women’s health, fertility, genetics, infectious diseases and preventive care; on-ground presence through 15 laboratories in a mix of metros and emerging cities; globally renowned bioinformatics capabilities used by global instrument providers and diagnostic laboratories; and access to India’s largest cancer biorepository for clinical research.
Amit Varma, Managing Partner and Co-Founder, Quadria Capital, said: “The demand for specialised diagnostics has been rising rapidly across the region. With diagnostics moving beyond just identification of infections to becoming an integral part of management and therapy, we see a huge potential in this area. Quadria is very excited to partner with Strand in this unique diagnostic platform that provides a potent combination of world class bio-informatics, genomics research, and integrated specialised diagnostics.”
Congratulating Strand Life Sciences on the agreement, industry veteran Kiran Mazumdar-Shaw, Chairman, Biocon, said: “Strand’s partnership with Triesta is an inflection point which I am confident will drive its future into the fast growing segment of genomic-led onco-diagnostics. This merger has attracted a significant investment from Quadria Capital which endorses the credibility of Strand’s evolving business strategy."